NCT05648448View on ClinicalTrials.gov

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

PHASE2RecruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
InfluenzaInfluenza, Human
Interventions
DRUG

Oseltamivir

Oral oseltamivir 75mg BD for 5/7

DRUG

Favipiravir

Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7

DRUG

Zanamivir

Inhaled zanamivir 10mg BD for 5/7

DRUG

Baloxavir

"Oral baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"

DRUG

Molnupiravir

Oral molnupiravir 800mg BD for 5/7

DRUG

Peramivir

Intravenous peramivir 600mg once only

DRUG

Laninamivir

Inhaled laninamivir 40mg once only

DRUG

Oseltamivir and Baloxavir

"Oseltamivir 75mg BD for 5/7 and~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"

DRUG

Oseltamivir and Favipiravir

"Oseltamivir 75mg BD for 5/7 and~favipiravir 1800mg BD D0 and 800mg BD for a further 4/7"

DRUG

Favipiravir and Baloxavir

"favipiravir 1800mg BD D0 and 800mg BD for a further 4/7~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"

Trial Locations (4)

10400

RECRUITING

Faculty of Tropical Medicine, Mahidol University, Bangkok

Unknown

RECRUITING

Universidade Federal de Minas Gerais, Minas Gerais

RECRUITING

Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane

RECRUITING

Sukraraj Tropical & Infectious Disease Hospital, Kathmandu

All Listed Sponsors
lead

University of Oxford

OTHER